Optiscan Imaging (ASX:OIL) has secured its first order into the U.S. market for its new generation ViewnVivo Preclinical System through its North American distributor, Scintica Instrumentation Inc.
Scintica has agreed an indicative minimum number of ViewnVivo systems which would deliver a revenue in excess of $1 million in the next 12 months.
Optiscan’s shares were last trading 12.5% higher intra-day, at $0.09.
The company manufactures high-resolution miniaturised confocal endomicroscopes (instrument to view submicron resolution images in detail) for clinical and preclinical research markets.
In September 2017, Optiscan and Scintica will have a major presence at the World Molecular Imaging Congress to be held in Philadelphia, U.S.
It is the leading global imaging conference for senior academic and industry professionals.
This is the optimal target group to benefit from the use of the ViewnVivo system and represents a significant opportunity to influence senior academic professionals.
Incidentally, Optiscan is expected to shortly execute an exclusive distribution agreement in China with its preferred distribution partner.
The company already has received confirmation from leading Chinese research institutes regarding their intent to purchase ViewnVivo systems.
Optiscan’s direct activity with distributors and potential customers in China indicates that it would receive confirmed ViewnVivo orders in the 2017 calendar year and beyond.